دورية أكاديمية
أعرض في EDS

Optical Coherence Tomography Angiography Retinal Imaging Associations With Burden of Small Vessel Disease and Amyloid Positivity in the Brain.

التفاصيل البيبلوغرافية
العنوان: Optical Coherence Tomography Angiography Retinal Imaging Associations With Burden of Small Vessel Disease and Amyloid Positivity in the Brain.
المؤلفون: Bermudez C; Department of Neurology (CB, VKR, DSK, AAR, RCP, JG-R, JJC), Mayo Clinic, Rochester, Minnesota; Center for Drug Design (SSM), College of Pharmacy, University of Minnesota, Minneapolis, Minnesota; Departments of Radiology (PMC, CRJ, PV) and Ophthalmology (JJC), Mayo Clinic, Rochester, Minnesota; and Department of Quantitative Health Sciences (TGL), Mayo Clinic, Rochester, Minnesota., Lesnick TG, More SS, Ramanan VK, Knopman DS, Rabinstein AA, Cogswell PM, Jack CR Jr, Vemuri P, Petersen RC, Graff-Radford J, Chen JJ
المصدر: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society [J Neuroophthalmol] 2024 Aug 01. Date of Electronic Publication: 2024 Aug 01.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9431308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-5166 (Electronic) Linking ISSN: 10708022 NLM ISO Abbreviation: J Neuroophthalmol Subsets: MEDLINE
أسماء مطبوعة: Publication: <1999->: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: New York, NY : Raven Press, c1994-
مستخلص: Background: Alzheimer disease (AD) and other dementias are associated with vascular changes and amyloid deposition, which may be reflected as density changes in the retinal capillaries. These changes may can be directly visualized and quantified with optical coherence tomography angiography (OCTA), making OCTA a potential noninvasive preclinical biomarker of small vessel disease and amyloid positivity. Our objective was to investigate the feasibility of retinal imaging metrics as noninvasive biomarkers of small vessel disease and amyloid positivity in the brain.
Methods: We investigated associations between OCTA and neuroimaging and cognitive metrics in 41 participants without dementia from the Mayo Clinic Study of Aging and Alzheimer's Disease Research Center. OCTA metrics included superficial, deep, and full retina capillary density of the fovea, parafovea, and macula as well as the area of the foveal avascular zone (FAZ). Neuroimaging metrics included a high burden of white matter hyperintensity (WMH), presence of cerebral microbleeds (CMB), lacunar infarcts, and amyloid positivity as evidenced on positron emission tomography (PET), whereas cognitive metrics included mini-mental status examination (MMSE) score. We performed generalized estimating equations to account for measurements in each eye while controlling for age and sex to estimate associations between OCTA metrics and neuroimaging and cognitive scores.
Results: Associations between OCTA and neuroimaging metrics were restricted to the fovea. OCTA showed decreased capillary density with high burden of WMH in both the superficial (P = 0.003), deep (P = 0.004), and full retina (P = 0.01) in the fovea but not the parafovea or whole macula. Similarly, participants with amyloid PET positivity had significantly decreased capillary density in the superficial fovea (P = 0.027) and deep fovea (P = 0.03) but higher density in the superficial parafovea (P = 0.038). Participants with amyloid PET positivity also had a significantly larger FAZ (P = 0.031), whereas in those with high WMH burden the difference did not reach statistical significance (P = 0.075). There was also a positive association between MMSE and capillary density of the full retina within the fovea (P = 0.037) and in the superficial parafovea (P = 0.046). No associations were found between OCTA metrics and presence of CMB or presence of lacunar infarcts.
Conclusion: The associations of lower foveal capillary density with cerebral WMH and amyloid positivity suggest that further research is warranted to evaluate for shared mechanisms of disease between small vessel disease and AD pathologies.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2024 by North American Neuro-Ophthalmology Society.)
References: Patton N, Aslam T, MacGillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat. 2005;206:319–348.
Katsimpris A, Karamaounas A, Sideri AM, Katsimpris J, Georgalas I, Petrou P. Optical coherence tomography angiography in Alzheimer's disease: a systematic review and meta-analysis. Eye. 2022;36:1419–1426.
Lahme L, Esser EL, Mihailovic N, et al. Evaluation of ocular perfusion in Alzheimer's disease using optical coherence tomography angiography. J Alzheimers Dis. 2018;66:1745–1752.
O'Bryhim BE, Apte RS, Kung N, Coble D, Van Stavern GP. Association of preclinical Alzheimer disease with optical coherence tomographic angiography findings. JAMA Ophthalmol. 2018;136:1242–1248.
Yoon SP, Grewal DS, Thompson AC, et al. Retinal microvascular and neurodegenerative changes in Alzheimer's disease and mild cognitive impairment compared with control participants. Ophthalmol Retina. 2019;3:489–499.
Van De Kreeke JA, Nguyen HT, Konijnenberg E, et al. Optical coherence tomography angiography in preclinical Alzheimer's disease. Br J Ophthalmol. 2020;104:157–161.
Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12:3555–3559.
Jack CR, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–547.
Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022;18:2669–2686.
Bermudez C, Graff-Radford J, Syrjanen JA, et al. Plasma biomarkers for prediction of Alzheimer's disease neuropathologic change. Acta Neuropathol. 2023;146:13–29.
Roseborough A, Ramirez J, Black SE, Edwards JD. Associations between amyloid β and white matter hyperintensities: a systematic review. Alzheimers Dement. 2017;13:1154–1167.
Van Dijk EJ, Prins ND, Vermeer SE, et al. Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol. 2004;55:570–575.
Graff-Radford J, Botha H, Rabinstein AA, et al. Cerebral microbleeds: prevalence and relationship to amyloid burden. Neurology. 2019;92:e253–e262.
de la Torre JC. The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. Neurodegener Dis. 2010;7:116–121.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association; 2013.
Jack CR Jr, Felmlee JP, Gunter JL, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–691.
Graff-Radford J, Aakre JA, Knopman DS, et al. Prevalence and heterogeneity of cerebrovascular disease imaging lesions. Mayo Clin Proc. 2020;95:1195–1205.
Arfanakis K, Evia AM, Leurgans SE, et al. Neuropathologic correlates of white matter hyperintensities in a community-based cohort of older adults. J Alzheimers Dis. 2020;73:333–345.
van Veluw SJ, Arfanakis K, Schneider JA. Neuropathology of vascular brain Health: insights from ex vivo magnetic resonance imaging-histopathology studies in cerebral small vessel disease. Stroke. 2022;53:404–415.
معلومات مُعتمدة: U01 AG006786 United States AG NIA NIH HHS; R01 AG034676 United States AG NIA NIH HHS; RF1 AG069052 United States AG NIA NIH HHS; MNP #18.06 University of Minnesota; Retinal Hyperspectral Imaging: A Tool for Early Detection of Alzheimer's Disease Minnesota Partnership for Biotechnology and Medical Genomics Grant
تواريخ الأحداث: Date Created: 20240801 Latest Revision: 20240801
رمز التحديث: 20240801
DOI: 10.1097/WNO.0000000000002230
PMID: 39085998
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5166
DOI:10.1097/WNO.0000000000002230